Amyloid-β (Aβ) and tau proteins currently represent the two most promising targets to treat
Alzheimer's disease. The most extensively developed method to treat the pathologic forms of …

The multifactorial and complex nature of Alzheimer's disease (AD) has made it difficult to
identify therapeutic targets that are causally involved in the disease process. However …

Intrinsically disordered proteins (IDPs) do not have rigid 3D structures, showing changes in
their folding depending on the environment or ligands. Intrinsically disordered proteins are …

Introduction Atrial fibrillation (AF) has been recognised as the most prevalent sustained
arrhythmia. Recently, a growing body of evidence has suggested that AF might be involved …

Introduction: Alzheimer's disease (AD) is the most important neurodegenerative disorder
with a global cost worldwide of over $700 billion. Pharmacological treatment accounts for 10 …

Simple Summary Tau protein is a microtubule-associated protein, widely known for its role in
neurodegenerative diseases. Recent studies show that Tau can also be involved in the …

The development of peptide-based vaccines for treating human neurodegenerative
diseases has been the eventual aim of many research endeavors, although no active …

Alzheimer's disease (AD) is a chronic neurodegenerative disease affecting the elderly. AD is
associated with a progressive decline in memory and cognitive abilities, drastic changes in …

Epilepsy is a common symptom of many neurological disorders and can lead to neuronal
damage that plays a major role in seizure-related disability. The peptidyl-prolyl isomerase …

Alzheimer's disease (AD) has been a worldwide concern for many years now. This is due to
the fact that AD is an irreversible and progressive neurodegenerative disease that affects …